Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective

Preoperative pembrolizumab combined with chemoradiotherapy for esophageal squamous cell carcinoma: Trial designCentral MessagePerspective

Objective: The safety and feasibility of preoperative pembrolizumab combined with chemoradiotherapy (PPCT) for resectable esophageal squamous cell carcinoma have been confirmed by the prior Preoperative Anti-PD-1 Antibody combined with Chemoradiotherapy for Locally Advanced Squmous Cell Carcinoma of...

Full description

Bibliographic Details
Main Authors: Yuyan Zheng, MD, Chengqiang Li, MD, PhD, Bentong Yu, MD, Shengguang Zhao, MD, Jian Li, MD, PhD, Xiaoyan Chen, MD, Hecheng Li, MD, PhD, FACS
Format: Article
Language:English
Published: Elsevier 2022-03-01
Series:JTCVS Open
Subjects:
esophageal squamous cell carcinoma
neoadjuvant therapy
chemoradiotherapy
immunotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666273621004228

Internet

http://www.sciencedirect.com/science/article/pii/S2666273621004228

Similar Items